Question · asked by 1 review
Sugammadex 2.0 mg/kg vs neostigmine (any dose): Risk of adverse events and serious adverse eventsb, bradycardia, PONV, and signs of residual neuromuscular blockade
- Population
- Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
- Intervention
- Sugammadex 2.0 mg/kg
- Comparison
- neostigmine (any dose)
- Outcome
- Risk of adverse events and serious adverse eventsb, bradycardia, PONV, and signs of residual neuromuscular blockade
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg Risks of adverse events and serious adverse eventsb, bradycardia, PONV, and signs of residual neuromuscular blockade · adult patients, ASA I to IV, who received non‐depolarizing NMBAs The review found no eligible studies for this question. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults (2017) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults 2017 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.